



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/077,928	02/20/2002	Howard Murad	2267-024	2267-024 7746	
9629	7590 04/22/2004		EXAMINER		
MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW			KIM, VICKIE Y		
	SYLVANIA AVENUE NV ON, DC 20004	/	ART UNIT	PAPER NUMBER	
	,		1614		
			DATE MAILED: 04/22/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	10/077,928	MURAD, HOWARD	
Advisory Action	Examiner	Art Unit	
	Vickie Kim	1614	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
Therefore, further action by the applicant is required to avainal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.) a timely filed amendment which I (with appeal fee); or (3) a timel	ation. A proper repl n places the applica	ition in
	EPLY [check either a) or b)]		
a) The period for reply expiresmonths from the mailin b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of the europe of the expiration date of the expiration	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply be later than three months after the main	g date of the final rejecting FINAL REJECTION. R 1.136(a) and the appropertion of the fee. The appropriginally set in the final	on. See MPEP opriate extension ropriate extension Office action; or
 A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR 	Brief must be filed within the pe R 1.191(d)), to avoid dismissal o	eriod set forth in f the appeal.	
2. The proposed amendment(s) will not be entered be	ecause:		
(a) 🛛 they raise new issues that would require further	er consideration and/or search (see NOTE below);	
(b) they raise the issue of new matter (see Note b	pelow);		•
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or si	mplifying the
(d) they present additional claims without canceli	ng a corresponding number of f	inally rejected claim	S.
NOTE: <u>See Continuation Sheet</u> .			
3. Applicant's reply has overcome the following reject			
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a se	eparate, timely filed	amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NO	T place the
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which wer	e newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: 23-34.			
Claim(s) withdrawn from consideration:			
8. The drawing correction filed on is a) app	roved or b)□ disapproved by t	he Examiner.	
9. Note the attached Information Disclosure Statement	nt(s)(PTO-1449) Paper No(s)	·	- 1
10. Other:	0	Webu PRIMARY	ie kim Examiner

Vickie Kim Primary Examiner Art Unit: 1614

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: The newly amended claims changed the scope of the claims wherein both an antimicrobial agent and an antiinflammatory agent must be included in the invetntio. Thus, the claims presented for the examination require further search and consideration.